- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03947047
Detection of Placenta Accreta Via Exhaled Women Breath
Detection of Placenta Accreta by Means of Volatile Organic Compounds in Exhaled Women Breath. A Prospective Case Control Study.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pregnant women with clinical risk factors for placenta accreta will perform targeted sonographic evaluation for detection of placenta accreta features, according to a standard protocol. Of those with clinical and sonographic risk factors who will agree to participate in the study, will be asked to breathe through a collection device (NA-NOSE) for "lung wash". The participant will be instructed to inhale through the device and exhale to the ambient air for about 3 minutes. After the lung wash step, the collector will inform the participant that she is about to start filling the collective bags. At the end of a regular breath, after exhaling, the collector will ask the participant to take a deep breath so the full volume of the lungs is filled, and then exhale until both the dead space bag and collection bag are full. After filling the first bag, a second bag will be placed and the participant will be asked to repeat the act. In addition, a venous blood sample of 8-10 ml will be taken from each participant.
The samples will be transferred to the Department of Chemical Engineering and Russell Berrie Nanotechnology Institute, Technion-Israel, Institute of Technology. The samples will be analyzed to determine the nature and composition of the volatile biomarkers in the related breath and blood samples.
In this way, the investigators will identify among women who have clinical and sonographic risk factors for placenta accreta, those biomarkers distinguishing women with placenta accreta (group 1) from those who will not have placenta accreta at birth (group 2).
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Raed Salim, MD
- Phone Number: +972-4-6494030
- Email: salim_ra@clalit.org.il
Study Contact Backup
- Name: Sivan Easton, MD
- Phone Number: +972-4-6494355
- Email: sivan_ea@clalit.org.il
Study Locations
-
-
-
Afula, Israel, 18101
- Recruiting
- Haemek Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnancy > 28 weeks of gestation.
- Agreement to participate and sign an informed consent.
- Ability to give breath and blood samples.
Risk factors for placenta accreta:
- Placenta previa.
- Previous 1 or more cesarean sections with placenta in the scar area.
Previous uterine procedures (myomectomy, curretage) and sonographic suspicion of abnormal placentation.
- Exclusion Criteria: None
-
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Placenta Accreta
Women found to have abnormal placentation (any degree of placenta accreta) during the cesarean section.
|
Breath and blood samples for distinguishing biomarkers.
|
No Placenta Accreta
Women found to have normal placenta separation during the cesarean section.
|
Breath and blood samples for distinguishing biomarkers.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Detection of placenta accreta
Time Frame: 2 years
|
The aim of the study is to improve pre-cesarean detection of placenta accreta using volatile biomarkers appearing in exhaled breath and/or blood samples, using a simple inexpensive tool termed NA-NOSE.
|
2 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Sivan Easton, MD, Emek Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0021-19-EMC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Placenta Accreta, Third Trimester
-
Ain Shams UniversityNot yet recruiting
-
Ain Shams UniversityUnknownPlacenta Accreta, Third TrimesterEgypt
-
Necmettin Erbakan UniversityRecruitingPlacenta Accreta, Third TrimesterTurkey
-
Cairo UniversityNot yet recruitingPlacenta Accreta, Third TrimesterEgypt
-
Necmettin Erbakan UniversityCompletedPlacenta Accreta, Third TrimesterTurkey
-
Assiut UniversityNot yet recruitingPlacenta Accreta, Unspecified Trimester
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Kasr El Aini HospitalUnknownPlacenta Accreta in Placenta Previa Anterior
-
Ain Shams Maternity HospitalCompleted
-
Sohag UniversityRecruiting
Clinical Trials on NA-NOSE
-
Carmel Medical CenterTechnion, Israel Institute of TechnologyCompletedMultiple SclerosisIsrael
-
Carmel Medical CenterTechnion, Israel Institute of TechnologyCompleted
-
Centre Hospitalier ArrasCompletedAcute Hypercapnic Respiratory FailureFrance
-
Hillel Yaffe Medical CenterUnknown
-
STEBA FranceSTEBA LABORATORIES LTD.CompletedGastroesophageal Reflux | Esophagitis | Duodenal Ulcer | Stomach UlcerUnited States
-
University Health Network, TorontoUnknown
-
Maastricht University Medical CenterNot yet recruiting
-
Hopital FochRecruitingTransplant; Complication, RejectionFrance
-
Erasmus Medical CenterRecruitingPulmonary FibrosisUnited Kingdom, Germany, Netherlands, France
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting